60.00% -0.0003

Syros Pharmaceuticals Inc (SYRS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Syros Pharmaceuticals Inc Stock (SYRS) Company Profile

Syros Pharmaceuticals Inc

Healthcare (1110)

Biotechnology (618)

Prossima data di guadagno

Ultimi documenti SEC

SYRS's Discussions on Twitter

Compare SYRS vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SYRS Syros Pharmaceuticals Inc	0.0002	0	9.94M	-97.82M	-100.02M	-3.07
VRTX Vertex Pharmaceuticals Inc	486.03	126.21B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	790.81	82.64B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	756.76	47.46B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	325.07	44.15B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	314.36	35.08B	4.98B	69.60M	525.67M	0.5198

Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2020-11-04	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-09-22	Iniziato	Alliance Global Partners	Buy
2020-01-17	Downgrade	Wedbush	Outperform → Neutral
2019-03-08	Ripresa	JMP Securities	Mkt Outperform
2019-02-14	Ripresa	Oppenheimer	Outperform
2018-11-05	Aggiornamento	ROTH Capital	Neutral → Buy
2018-03-13	Reiterato	Wedbush	Outperform
2017-10-31	Ripresa	Piper Jaffray	Overweight
2017-10-23	Iniziato	ROTH Capital	Neutral
2017-08-10	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform

Mostra tutto

Syros Pharmaceuticals Inc Borsa (SYRS) Ultime notizie

Syros Pharmaceuticals Inc Azioni (SYRS) Dati Finanziari

Syros Pharmaceuticals Inc (SYRS)

Syros Pharmaceuticals Inc Stock (SYRS) Company Profile

Compare SYRS vs VRTX, REGN, ARGX, ALNY, ONC

Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades

Syros Pharmaceuticals Inc Borsa (SYRS) Ultime notizie

MSN - MSN

MSN Money - MSN

Myelodysplastic Syndrome Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Globe and Mail

Reviewing Vectura Group (OTCMKTS:VEGPF) and Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World

Head-To-Head Review: Aerovate Therapeutics (NASDAQ:AVTE) vs. Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World

Syros to delist from Nasdaq, deregister from SEC - MSN

SYRS (Syros Pharmaceuticals) Price-to-Tangible-Book : (As of Oct. 22, 2025) - GuruFocus

CapEx per share of Syros Pharmaceuticals, Inc. – OTC:SYRS - TradingView

Syros stock dives 92% on failed Phase 3 study, possible loan default (update) - MSN

Net current asset value per share of Syros Pharmaceuticals, Inc. – OTC:SYRS - TradingView

JMP Securities Downgrades Syros Pharmaceuticals (SYRS) - MSN

AKPKD Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeut - The Globe and Mail

Myelodysplastic Syndrome Pipeline Analysis, 2025 by DelveInsight | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, - Barchart.com

Syros Pharmaceuticals, Inc. (SYRS) stock price, news, quote and history - Yahoo Finance Singapore

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital - GlobeNewswire

Syros Pharmaceuticals (SYRS) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat

SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative

Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire

SYRS Stock Price, News & Analysis - stocktitan.net

Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus

Syros Pharma pulls out of deal with RaQualia - The Pharma Letter

SYRS Stock Price and Chart — OTC:SYRS - TradingView

Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga

Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights

US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga

Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com

Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), State Street SPDR S&P 500 ETF Trust (ARCA:SPY) - Benzinga

Failed Clinical Trial Forces Syros Pharmaceuticals Into Delisting and Wind-Down Operations - Stock Titan

Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - MSN

Syros Pharmaceuticals stock plunges to 52-week low of $0.16 - Investing.com

Odyssey hires Jason Haas as CFO - BioCentury

Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com

BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President - Business Wire

Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com Australia

Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 By Investing.com - Investing.com Australia

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN

Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com

Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges - Nasdaq

Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - Yahoo Finance

No RARA, Syros trouble: MDS phase III sinks tamibarotene - BioWorld MedTech

Syros stock dives 92% on failed Phase 3 study, possible loan default (NASDAQ:SYRS) - Seeking Alpha

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update - Business Wire

CDK 7 Inhibitors Market is Expected to Showcase a Significant Growth by 2034 | DelveInsight - The Malaysian Reserve

Syros Pharmaceuticals Chief Financial Officer Acquires 407% More Stock - simplywall.st

Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS) - Yahoo Finance

Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gew - GuruFocus

Syros Pharmaceuticals, Inc. (SYRS) Investigation: - GlobeNewswire

Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings - Business Wire

How to contact the Daily Bulletin - FinancialContent

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - PR Newswire

Syros Pharmaceuticals Inc Azioni (SYRS) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a SYRS